Neurotech International (ASX:NTI) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Neurotech International is: No Data: Cannot be evaluated.

Competitive Comparison of Neurotech International's Risk Assessment

For the Medical Devices subindustry, Neurotech International's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurotech International's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Neurotech International's Risk Assessment falls into.

Neurotech International (ASX:NTI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Neurotech International Risk Assessment Related Terms

Thank you for viewing the detailed overview of Neurotech International's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurotech International (ASX:NTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.neurotechinternational.com

Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

9 Stocks with Double-Digit Yields and Buy or Better Recommendations

By Dividend Dividend • 07-17-2013

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend • 11-12-2014

By Dividend Dividend • 06-25-2013

18 Stocks with Very High Yields (More Than 10%) and Earnings Growth

By Dividend Dividend • 12-20-2012

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson • 11-09-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend • 08-17-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend • 01-17-2013